Value appropriation in hepatitis C
Year of publication: |
2022
|
---|---|
Authors: | Lindgren, Peter ; Löfvendahl, Sofia ; Brådvik, Gunnar ; Weiland, Ola ; Jönsson, Bengt |
Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 23.2022, 6, p. 1059-1070
|
Subject: | Consumer surplus | Cost-effectiveness | Hepatitis C | Pharmaceutical reimbursement | Producer surplus | Konsumentenrente | Arzneimittel | Pharmaceuticals | Theorie | Theory | Infektionskrankheit | Infectious disease | Gesundheitskosten | Health care costs | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Pharmaindustrie | Pharmaceutical industry |
-
Kuhlmann, Alexander, (2017)
-
Are biopharmaceutical budget caps good public policy?
Goldman, Dana P., (2016)
-
Coyle, Doug, (2024)
- More ...
-
Costs and quality of life in multiple sclerosis : a cross-sectional observational study in Germany
Kobelt, Gisela, (2000)
-
Cost-effectiveness of statins revisited : lessons learned about the value of innovation
Lindgren, Peter, (2012)
-
Costs and quality of life in multiple sclerosis in Europe : method of assessment and analysis
Kobelt, Gisela, (2006)
- More ...